• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biophys Chem . Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M pro) inhibitor of novel SARS-CoV-2 virus identified us

tetano

Editor, Senior Moderator
Biophys Chem


. 2020 Jul 6;264:106425.
doi: 10.1016/j.bpc.2020.106425. Online ahead of print.
Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M [SUP]pro[/SUP]) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation


Priyashi Rao[SUP] 1 [/SUP], Arpit Shukla[SUP] 2 [/SUP], Paritosh Parmar[SUP] 2 [/SUP], Rakesh M Rawal[SUP] 1 [/SUP], Baldev Patel[SUP] 2 [/SUP], Meenu Saraf[SUP] 2 [/SUP], Dweipayan Goswami[SUP] 3 [/SUP]



Affiliations

Abstract

The novel SARS-CoV-2 is the etiological agent causing the Coronavirus disease 2019 (COVID-19), which continues to become an inevitable pandemic outbreak. Over a short span of time, the structures of therapeutic target proteins for SARS-CoV-2 were identified based on the homology modelled structure of similar SARS-CoV transmission of 2003. Since the onset of the disease, the research community has been looking for a potential drug lead. Out of all the known resolved structures related to SARS-CoV, Main protease (M[SUP]pro[/SUP]) is considered an attractive anti-viral drug target on the grounds of its role in viral replication and probable non-interactive competency to bind to any viral host protein. To the best of our knowledge, till date only one compound has been identified and tested in-vivo as a potent inhibitor of M[SUP]pro[/SUP] protein, addressed as N3 (PubChem Compound CID: 6323191) and is known to bind irreversibly to M[SUP]pro[/SUP] suppressing its activity. Using computational approach, we intend to identify a probable natural fungal metabolite to interact and inhibit M[SUP]pro[/SUP]. After screening various small molecules for molecular docking and dynamics simulation, we propose Pyranonigrin A, a secondary fungal metabolite to possess potent inhibitory potential against the Main protease (M[SUP]pro[/SUP]) expressed in SARS-CoV-2 virus.

Keywords: Docking; Fungal metabolites; Main protease (M(pro)); Molecular dynamics simulation; SARS-CoV-2 novel corona virus.
 
Back
Top Bottom